[6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer)

Exhibit 99.1

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: mail@drreddys.com

Web: www.drreddys.com

May 12, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Sub: Outcome of Board Meeting held on May 12, 2026

Dear Sir/Madam,

In continuation to our letters dated March 23, 2026, and April 16, 2026, we would like to inform that the Board of Directors of the Company, at its meeting held today, i.e., May 12, 2026, inter alia considered and approved the following:

1.

Audited Financial Results

Approved the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026. Accordingly, the following are enclosed:

a)

Audited Consolidated Financial Results of the Company, as per the International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB).

b)

Press Release on Audited Financial Results.

c)

Audited Consolidated Financial Results of the Company, as per Indian Accounting Standards (Ind AS).

d)

Audited Standalone Financial Results of the Company (Ind AS)

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“SEBI Listing Regulations”), the Audit Reports of the Statutory Auditors on the aforesaid financial results are enclosed.

A declaration under Regulation 33(3)(d) of the SEBI Listing Regulations, signed by Chief Financial Officer in respect of Audit Reports issued by Statutory Auditors with un-modified opinion is attached herewith.

2.

Dividend

Recommended a final dividend of INR 8/- per equity share of face value of Rs. 1/- each for the financial year 2025-26, subject to approval of shareholders at the ensuing Annual General Meeting. Pursuant to Regulation 42 of SEBI Listing Regulations, the record date for determining the members eligible to receive the said dividend has been fixed as July 10, 2026.

3.

Annual General Meeting

Approved convening of the 42^nd Annual General Meeting (“AGM”) of the Company on Thursday, July 23, 2026.

4.

Re-appointment of Dr. K P Krishnan (DIN: 01099097) as an Independent Director

Approved re-appointment of Dr. K P Krishnan (DIN: 01099097) as an Independent Director for a second term of five consecutive years from January 7, 2027 to January 6, 2032, not liable to retire by rotation, subject to approval of the shareholders at the ensuing AGM.

Dr. Krishnan is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. He meets the criteria for being re-appointed as an Independent Director under the applicable laws.

5.

Appointment of Mr. Srikanth Velamakanni (DIN: 01722758) as an Independent Director

Approved appointment of Mr. Srikanth Velamakanni (DIN: 01722758) as an Additional Director, categorized as an Independent Director, for a term of five consecutive years, from July 1, 2026 to June 30, 2031, not liable to retire by rotation, subject to approval of shareholders at the ensuing AGM.

Mr. Srikanth is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. He meets the criteria for being appointed as an Independent Director under the applicable laws.

6.

Appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants as Statutory Auditors

Approved appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants (Firm Registration No. 117366W/W-100018), as the Statutory Auditors of the Company, for a term of five consecutive years, commencing from the conclusion of the 42^nd AGM till the conclusion of the 47^th AGM, subject to the approval of the shareholders at the ensuing AGM.

7.

Re-appointment of M/s Sagar & Associates, Cost Accountants as Cost Auditors

Approved re-appointment of M/s Sagar & Associates, Cost Accountants (Firm Registration No. 000118), as the Cost Auditors of the Company for the Financial Year 2026-27.

8.

Elevation of Mr. Sandeep Khandelwal as a Senior Management Personnel

Approved elevation of Mr. Sandeep Khandelwal, Global Generics India Head, as a Senior Management Personnel of the Company and induction as a member of the Management Council, effective May 12, 2026. The revised list of Senior Management Personnel is attached.

The disclosures required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are attached as Annexures.

The Board Meeting commenced at 2:00 PM IST and concluded at 3:47 PM IST.

This is for your information and records.

Thanking you.

Yours faithfully,

For Dr. Reddy’s Laboratories Limited

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Encl: as above

Details of Dr. K P Krishnan (DIN: 01099097)

Sl.no.	Particulars	Details
1.	Reason for change viz. ~~appointment,~~ re-appointment~~, resignation, removal, death or otherwise~~	Re-appointment
2.	Date of ~~appointment~~/re-appointment/~~cessation~~ (as applicable) & term of ~~appointment~~/re-appointment	Based on the recommendation of the Nomination, Governance and Compensation Committee, the Board has approved the re-appointment of Dr. K P Krishnan (DIN: 01099097) as an Independent Director of the Company for a second term of five consecutive years from January 7, 2027 to January 6, 2032, not liable to retire by rotation, subject to approval of the shareholders at the ensuing AGM.
3.	Disclosure of relationships between directors (in case of appointment of a director)	Dr. K P Krishnan is not related to any of the Directors of the Company

Brief Profile of Dr. Krishnan:

Dr. K.P. Krishnan is a former IAS officer with 37 years of distinguished service in public policy, economic governance, and regulatory reform across the Government of India, Government of Karnataka, and the World Bank. He has held key national leadership roles, including Secretary, Ministry of Skill Development and Entrepreneurship; Additional/Special Secretary in the Ministries of Finance and Rural Development; and Secretary to the Prime Minister’s Economic Advisory Council.

A respected academician, he has taught at IIM Bangalore, ISB, and Ashoka University, held the Bok Visiting Professorship at the University of Pennsylvania Law School, and served as IEPF Chair Professor at NCAER, New Delhi. He is currently a Distinguished Fellow at the Isaac Centre for Public Policy, Ashoka University.

Dr. Krishnan serves on the boards and advisory councils of several leading corporates and non-profits, including Dr. Reddy’s Laboratories, Tata Consumer Products, Shriram Capital, ASREC India, Helios Trustee, Razorpay, and the Sanmar Group. He holds degrees in Economics (St. Stephen’s College), Law (Campus Law Centre, University of Delhi), and a Ph.D. in Economics (IIM Bangalore).

Details of Mr. Srikanth Velamakanni (DIN: 01722758)

Sl.no.	Particulars	Details
1.	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Appointment
2.	Date of appointment/~~re-appointment/cessation~~ (as applicable) & term of appointment/re-appointment	Based on the recommendation of the Nomination, Governance and Compensation Committee, the Board has approved the appointment of Mr. Srikanth Velamakanni (DIN: 01722758) as an Additional Director, categorized as an Independent Director for a term of five consecutive years, effective from July 1, 2026 to June 30, 2031, not liable to retire by rotation, subject to approval of shareholders at the ensuing AGM.
3.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Srikanth Velamakanni is not related to any of the Directors of the Company

Brief Profile: Mr. Srikanth Velamakanni

Mr. Srikanth Velamakanni is one of India’s most influential technology leaders and a global champion of artificial intelligence. He is the Co-Founder and Group Chief Executive of Fractal, India’s first publicly listed pure-play AI company. He also serves as the Chairperson of Nasscom and as a Founder-Trustee of Plaksha University. Srikanth's work is guided by a long-term commitment to building technology that expands human potential.

Details of Statutory Auditors

Sl.no.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, ~~resignation, removal, death or otherwise~~	Appointment
2.	Date of appointment/~~re-appointment/cessation~~ (as applicable) & term of appointment/re-appointment	Based on the recommendation of the Audit Committee, the Board has approved the appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants (Firm Registration No. 117366W/W-100018), as the Statutory Auditors of the Company, for a term of five consecutive years, commencing from the conclusion of the 42^nd Annual General Meeting (AGM) till the conclusion of the 47^th AGM, subject to the approval of the shareholders at the ensuing AGM.
3.	Brief profile (in case of appointment)	Deloitte Haskins & Sells, Mumbai was constituted in 1997 and has been converted to a Limited Liability Partnership (LLP), with the name Deloitte Haskins & Sells LLP ("“DHS LLP”" or "“Firm"”), w.e.f. November 20, 2013. DHS LLP is registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018) and is a part of Deloitte Haskins & Sells & Affiliates being the Network of Firms registered with the ICAI. The registered office of the Firm is One International Center, Tower 3, 31st Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai - 400013, Maharashtra, India.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Details of Cost Auditors

Sl.no.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, ~~resignation, removal, death or otherwise~~	Re-appointment
2.	Date of appointment/~~re-appointment/cessation~~ (as applicable) & term of appointment/re-appointment	Based on the recommendation of the Audit Committee, the Board has approved the re-appointment of M/s Sagar & Associates, Cost Accountants (Firm Registration No. 000118), as the Cost Auditors of the Company for the Financial Year 2026-27.
3.	Brief profile (in case of appointment)	M/s Sagar & Associates, Cost Accountants (Firm Registration No. 000118) is a peer reviewed leading firm of Cost & Management Accountants having diversified activities in cost and management accounting area. The firm consisting of qualified cost accountants has undertaken many assignments in various industries. The registered office of the Firm is at 205, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad – 500001
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Details of Mr. Sandeep Khandelwal

Sl.no.	Particulars	Details
1.	Reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise~~	Elevation of Mr. Sandeep Khandelwal, Global Generics India Head as Senior Management Personnel
2.	Date of appointment/~~re-appointment/cessation~~ (as applicable) & term of appointment/re-appointment	Based on the recommendation of the Nomination, Governance and Compensation Committee, the Board has approved elevation of Mr. Sandeep Khandelwal, Global Generics India Head as Senior Management Personnel of the Company and his induction as a Member of Management Council, effective from May 12, 2026.
3.	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

Brief Profile of Mr. Sandeep Khandelwal

Sandeep Khandelwal brings 26 years of leadership experience across General Management, Sales, Marketing and functional roles, with deep sectoral expertise spanning Pharmaceuticals, OTC, FMCG and Consumer Durables and extensive exposure across South Asia.

Sandeep joined Dr. Reddy’s Laboratories in 2018 and currently heads the India sub-continent business, a USD 750 million operation spanning India, Nepal, Sri Lanka, Myanmar, Maldives and Mauritius. He leads a 10,000-strong organization across more than 45 divisions and six countries.

Over the last seven years, Sandeep has led a significant transformation of Dr. Reddy’s India business, evolving it from a branded generics-centric model into a multi-engine organization, with innovative assets and consumer businesses shaping the next phase of growth. During this period, the India topline has grown from Rs 2,300 crore to Rs 7,000 crore, EBITDA margins have expanded from 19 percent to 24 percent, and the company’s market rank in India has improved from 16th to 9th. The business has consistently delivered quarter-on-quarter market-beating growth over the last 1.5 years.

He has shaped and is executing a clear strategic agenda focused on strengthening core brands, sharpening portfolio choices and structurally improving profitability. The emphasis has been on elevating business quality through higher throughput efficiency, disciplined gross-to-net management and selective pruning of non-core elements, while progressively refreshing the portfolio through differentiated internal R&D-led launches and curated in-licensing partnerships with global and regional pharmaceutical players. In parallel, he instituted strong medical and marketing excellence capabilities to anchor a sustained, multi-year growth runway for the company’s flagship brands.

Sandeep has embedded a strong “Playing to Win” performance culture across the organization and accelerated the adoption of digital and multi-channel engagement models, resulting in a 14 percent improvement in field force productivity. He has also led complex change-management efforts across employees, channel partners, trade bodies and employee unions.

Key milestones under his leadership include the Wockhardt and Novartis acquisitions, the establishment of the Nestlé–Dr. Reddy’s Nutrition joint venture, and expansion across high-growth platforms such as Vaccines, Biologics, Nutrition, OTC, E-commerce, Trade Generics, alternate channels and rural markets.

Prior to Dr. Reddy’s, Sandeep held senior leadership roles at Abbott India, including Commercial Director for Women’s Health, Gastroenterology, Hepatic and OTC therapies, and Director, Commercial Excellence. Earlier in his career at Marico Limited, he held multiple frontline and enterprise leadership roles across sales, trade marketing, channel development and regional management, including heading sales for the Rs. 2,100 crore personal care portfolio.

Sandeep has also driven a step-change in leadership diversity, significantly enhancing gender diversity and diversity of thought within leadership and commercial teams. He actively represents the organization at leading industry forums such as FICCI and the Indian Pharmaceutical Alliance. Key recognitions include being named among the “40 Under 40: Hottest Business Leaders” by The Economic Times in association with Spencer Stuart.

List of revised Senior Management Personnel

Sl.No	Name of the SMP	Designation
1	Mr. Satish Reddy	Chairman and Whole-time Director
2	Mr. G V Prasad	Co-Chairman and Managing Director (KMP)
3	Mr. Erez Israeli	Chief Executive Officer (KMP)
4	Mr. M V Ramana	CEO Global Generics
5	Mr. Sanjay Sharma	Chief Operating Officer
6	Mr. M V Narasimham	Chief Financial Officer (KMP)
7	Mr. Deepak Sapra	Chief Executive Officer, API and Services
8	Mr. Krishna Venkatesh	Global Head of IPDO - Integrated Product Development Organization
9	Mr. Patrick Aghanian	Head - Consumer Health Organization
10	Mr. Phanimitra B	Chief Digital and Information Officer
11	Mr. Milan Kalawadia	Chief Executive Officer, North America
12	Mr. M S Madhu Sundar	Global Head of Quality and PV
13	Mr. Sandeep Khandelwal	Global Generics India Head
14	Mr. K Randhir Singh	Company Secretary, Compliance Officer and Head-CSR (KMP)

Exhibit 99.2

CONTACT

DR. REDDY'S LABORATORIES LTD.

Investor relationS

Media relationS

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500034. Telangana, India.

AISHWARYA SITHARAM

aishwaryasitharam@drreddys.com

PRIYA K

priyak@drreddys.com

Dr. Reddy’s Q4 & Full Year FY26 Financial Results

Hyderabad, India, May 12, 2026: Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2026. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS).

Particulars	Q4FY26	FY26

*Revenues¹*	₹ 75,162 Mn [Down: 11.6% YoY; 13.9% QoQ]	₹ 335,933 Mn [Up: 3.2% YoY]

*Gross Margin²*	44.8% [Q4FY25: 55.6%; Q3FY26: 53.6%]	52.8% [FY25: 58.5%]

*EBITDA³*	₹ 9,807 Mn [13.0% of Revenues]	₹ 76,595 Mn [22.8% of Revenues]

*Profit before Tax⁴*	₹ 1,991 Mn [2.6% of Revenues]	₹ 54,817 Mn [16.3% of Revenues]

*Profit after Tax* attributable to Equity Holders	₹ 2,201 Mn [2.9% of Revenues]	₹ 42,850 Mn [12.8% of Revenues]

Notes: The results include the adverse impact of a Shelf Stock Adjustment (‘SSA’) related to lenalidomide of ₹ 4,530 Mn, impairment of CAR-T assets and Eftilagimod Alfa of a total of ₹2,277 Mn, provisions related to VAT liability of ₹1,141 Mn in Q4FY26. In addition to the above, FY26 includes adverse impact of VAT liability provision of ₹695 Mn and New Labour Codes of ₹ 1,170 Mn. The above items impacted :

·

Revenue growth by 5.3% YoY and 5.2% QoQ in Q4FY26 and 1.4% in FY26.

·

Gross Margin by 3.2% in Q4FY26 and 0.7% in FY26.

·

EBITDA Margin by 6.5% in Q4FY26 and 1.9% in FY26.

·

PBT Margin by 9.9% in Q4FY26 and 2.7% in FY26.

Commenting on the results, Co-Chairman & MD, G V Prasad said: “Our performance this year reflects the impact of lower lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact. We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimization. In parallel, we continue to build long-term franchises in biosimilars, consumer health and innovation to deliver sustainable value.”

1

All amounts in millions, except EPS

All US dollar amounts based on convenience translation rate of 1 USD = ₹93.83

Dr. Reddy’s Laboratories Limited & Subsidiaries

Revenue Mix by Segment for the quarter

Particulars	Q4FY26		Q4FY25		YoY			Q3FY26		QoQ
	(₹)		(₹)		Gr %			(₹)		Gr %
Global Generics		65,802		75,365		(13	)		79,113		(17	)
North America		17,562		35,586		(51	)		29,644		(41	)
Emerging Markets		18,057		13,981		29			18,961		(5	)
India		15,663		13,047		20			16,032		(2	)
Europe		14,520		12,750		14			14,476		0.3
Pharmaceutical Services and Active Ingredients (PSAI)		9,124		9,563		(5	)		8,018		14
Others		236		132		79			137		73
Total		75,162		85,060		(12	)		87,268		(14	)

Revenue Mix by Segment for the year

Particulars	FY26		FY25		YoY
	(₹)		(₹)		Gr%
Global Generics		299,033		289,552		3
North America		113,737		1,45,164		(22	)
Emerging Markets		67,608		54,772		23
India		62,186		53,734		16
Europe		55,501		35,882		55^
PSAI		34,774		33,846		3
Others		2,127		2,137		(0	)
Total		335,933		325,535		3

^Excluding acquired Consumer Healthcare business in Nicotine Replacement Therapy (NRT) sales; revenue growth is at 14% YoY.

2

Consolidated Income Statement for the quarter

Particulars	Q4FY26						Q4FY25						YoY			Q3FY26						QoQ
	($)			(₹)			($)			(₹)			Gr%			($)			(₹)			Gr%
Revenues	801			75,162			907			85,060			(12)			930			87,268			(14)
Cost of Revenues		442			41,471			403			37,797			10			431			40,462			2
Gross Profit		359			33,691			504			47,263			(29	)		499			46,806			(28	)
% of Revenues					44.8	%					55.6	%								53.6	%
Selling, General & Administrative Expenses		296			27,762			256			24,055			15			287			26,918			3
% of Revenues					36.9	%					28.3	%								30.8	%
Research & Development Expenses		58			5,463			77			7,258			(25	)		66			6,149			(11	)
% of Revenues					7.3	%					8.5	%								7.0	%
Impairment of Non-Current Assets, net		28			2,586			8			768			237			3			271			854
Other (Income)/Expense, net		(37	)		(3,445	)		(26	)		(2,465	)		40			(8	)		(770	)		347
Results from Operating Activities		14			1,325			188			17,647			(92	)		152			14,238			(91	)
Finance (Income)/Expense, net		(7	)		(620	)		(25	)		(2,352	)		(74	)		(12	)		(1,168	)		(47	)
Share of Profit of Equity Investees, net of tax		(0	)		(46	)		(1	)		(55	)		(16	)		(0	)		(23	)		100
Profit before Income Tax		21			1,991			214			20,054			(90	)		164			15,429			(87	)
% of Revenues					2.6	%					23.6	%								17.7	%
Income Tax Expense/(Benefit)		(2	)		(214	)		45			4,181			(105	)		38			3,533			(106	)
Profit for the Period		23			2,205			169			15,873			(86	)		127			11,896			(81	)
% of Revenues					2.9	%					18.7	%								13.6	%
Attributable to Equity holders of the Parent Co.		23			2,201			170			15,939			(86	)		128			12,098			(82	)
% of Revenues					2.9	%					18.7	%								13.9	%
Attributable to Non-controlling interests		0.04			3			(1	)		(66	)		(105	)		(1	)		(202	)		(102	)
Diluted Earnings per Share (EPS)		0.03			2.64			0.18			16.94			(84	)		0.15			14.51			(82	)

Earnings before Interest, Tax, Depreciation & Amortization (EBITDA) Computation for the quarter

Particulars	Q4FY26						Q4FY25						Q3FY26
	($)			(₹)			($)			(₹)			($)			(₹)
Profit before Income Tax		21			1,991			214			20,054			164			15,429
Interest (Income) / Expense, net*		(4	)		(346	)		(7	)		(627	)		(4	)		(422	)
Depreciation		37			3,459			28			2,636			34			3,178
Amortization		23			2,117			20			1,919			22			2,037
Impairment		28			2,586			8			768			3			271
EBITDA		105			9,807			264			24,749			218			20,493
% of Revenues					13.0	%					29.1	%					23.5	%

*Includes income from Investment

3

Consolidated Income Statement for the year

Particulars	FY26						FY25						YoY
	($)			(₹)			($)			(₹)			Gr%
Revenues		3,580			335,933			3,469			325,535			3
Cost of Revenues		1,691			158,669			1,440			135,107			17
Gross Profit		1,889			177,264			2,030			190,428			(7	)
% of Revenues					52.8	%					58.5	%
Selling, General & Administrative Expenses		1,138			106,763			1,000			93,870			14
% of Revenues					31.8	%					28.8	%
Research & Development Expenses		256			24,058			292			27,380			(12	)
% of Revenues					7.2	%					8.4	%
Impairment of Non-Current Assets, net		38			3,519			18			1,693			108
Other (Income)/Expense, net		(81	)		(7,627	)		(46	)		(4,358	)		75
Results from Operating Activities		539			50,551			766			71,843			(30	)
Finance (Income)/Expense, net		(44	)		(4,132	)		(50	)		(4,724	)		(13	)
Share of Profit of Equity Investees, net of tax		(1	)		(134	)		(2	)		(217	)		(38	)
Profit before Income Tax		584			54,817			818			76,784			(29	)
% of Revenues					16.3	%					23.6	%
Income Tax Expense		132			12,351			208			19,539			(37	)
Profit for the Period		453			42,466			610			57,245			(26	)
% of Revenues					12.6	%					17.6	%
Attributable to Equity holders of the Parent Co.		457			42,850			603			56,544			(24	)
% of Revenues					12.8	%					17.4	%
Attributable to Non-controlling interests		(4	)		(384	)		7			701			(155	)
Diluted Earnings per Share (EPS)		0.55			51.42			0.72			67.78			(24	)

EBITDA Computation for the year

Particulars	FY26						FY25
	($)			(₹)			($)			(₹)
Profit before Income Tax		584			54,817			818			76,784
Interest (Income) / Expense, net*		(25	)		(2,347	)		(36	)		(3,402	)
Depreciation		135			12,621			112			10,505
Amortization		85			7,985			70			6,553
Impairment		38			3,520			18			1,693
EBITDA		816			76,595			982			92,133
% of Revenues					22.8	%					28.3	%

*Includes income from Investment

Key Balance Sheet Items

Particulars	As on 31^st Mar 2026				As on 31^st Dec 2025				As on 31^st Mar 2025
	($)		(₹)		($)		(₹)		($)		(₹)
Cash and Cash Equivalents and Other Investments		1,050		98,509		929		87,191		728		68,299
Trade Receivables		1,079		101,219		1,100		103,206		964		90,420
Inventories		816		76,531		842		79,009		758		71,085
Property, Plant, and Equipment		1,236		115,930		1,231		115,544		1,042		97,761
Goodwill and Other Intangible Assets		1,257		117,952		1,223		114,727		1,158		108,613
Loans and Borrowings (Current & Non-Current)		824		77,341		722		67,732		498		46,766
Trade Payables		356		33,411		435		40,796		379		35,523
Equity		4,055		380,457		4,005		375,756		3,593		337,166

4

Key Business Highlights for Q4FY26

·

Received the Notice of Compliance from Pharmaceutical Drugs Directorate for generic Semaglutide injection in Canada, indicated for treatment of Type 2 diabetes.

·

Launched generic Semaglutide Injection in India for treatment of Type 2 diabetes, under the brand name ‘Obeda^®‘ on Day 1 of market formation post loss of exclusivity.

·

Received marketing authorization for generic Semaglutide tablets in India for treatment of Type 2 diabetes from Drugs Controller General of India (DCGI), following the recommendation of Subject Expert Committee (SEC) under Central Drugs Standard Control Organization (CDSCO).

·

Forayed into Hormone Replacement Therapy in India with acquisition of Progynova^® and related assets.

·

Acceptance for review by United States Food and Drug Administration (USFDA) of the Biologics License Application (BLA) for the Intravenous (IV) presentation of our abatacept biosimilar in the US.

·

Integration of 95% of acquired Consumer Healthcare business in Nicotine Replacement Therapy (NRT) business by value completed as of March 2026.

·

First-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the US.

·

Launched Tegoprazan in Russia, following a successful launch in India.

ESG Highlights for Q4FY26

·

Named by BusinessWorld among India’s Top 5 Most Sustainable Companies, ranking first in the Indian healthcare and pharmaceutical industry for 2024-25.

·

Recognized in the ‘Leadership Category’ of the 2025 Indian Corporate Governance Scorecard for the third consecutive year, jointly by Institutional Investor Advisory Services (IiAS), the International Finance Corporation (IFC) and the Bombay Stock Exchange (BSE).

Other Updates for Q4FY26

·

Received ‘VAI’ classification, following a GMP and a PAI conducted by the USFDA in December 2025 at formulations manufacturing facility, FTO-SEZ PU01, in Srikakulam, Andhra Pradesh, India.

·

Divested two non-core brands in India.

·

Discontinuation of trial of licensed novel drug candidate, Eftilagimod alfa, by partner, Immutep, following a planned interim futility analysis.

·

Discontinuation of certain R&D programs in CAR-T therapy, as part of portfolio rationalization.

·

The Board has recommended a dividend payment of Rs. 8 per equity share of face value Re. 1/- each (800% of face value) for year ended March 31, 2026, subject to shareholder approval.

5

Revenue Analysis

·

Q4FY26 consolidated revenues at ₹75.2 billion, decline of 11.6% YoY and 13.9% QoQ.

FY26 consolidated revenues at ₹335.9 billion, growth of 3.2% YoY.

Growth was broad-based across key markets, except for North America which declined primarily on account of lower Lenalidomide sales and a one-time Shelf Stock Adjustment (SSA) of ₹4.5 billion related to the product. Favourable foreign exchange rate movements further supported overall growth.

Excluding the one-time SSA, consolidated revenues were at ₹79.7 billion in Q4FY26, a decline of 6.3% YoY and 8.7% QoQ and ₹340.5 billion in FY26, a growth of 4.6% YoY.

Global Generics (GG)

·

Q4FY26 revenues at ₹65.8 billion, decline of 13% YoY and 17% QoQ.

FY26 revenues at ₹299.0 billion, growth of 3% YoY.

Excluding the one-time SSA mentioned above, revenues for the segment posted a decline of 7% YoY and 11% QoQ in Q4FY26 and a growth of 4.8% YoY in FY26.

North America

·

Q4FY26 revenues at ₹17.6 billion, decline of 51% YoY and 41% QoQ.

FY26 revenues at ₹113.7 billion, decline of 22% YoY.

Decline was largely due to lower Lenalidomide sales and the one-time SSA mentioned above.

Excluding this one-off, revenues for the segment posted a decline of 38% YoY and 25% QoQ in Q4FY26 and 19% YoY in FY26.

·

During the quarter, we launched seven new products, while a total of 25 new products were launched during FY26.

·

We filed five new Abbreviated New Drug Applications (ANDAs) with the USFDA during the quarter, taking the total to 15 for FY26.

·

As of March 31, 2026, filings pending approval from USFDA were 77 including:

-

75 ANDAs (43 are Paragraph IV applications, and 22 may have a ‘First to File’ status) and

-

Two New Drug Applications (NDAs) filed u/s 505(b)(2), of which one is a Paragraph IV application.

Emerging Markets

·

Q4FY26 revenues at ₹18.1 billion, growth of 29% YoY and a decline of 5% QoQ.

FY26 revenues at ₹67.6 billion, growth of 23% YoY.

YoY growth was largely driven by new launches across markets and higher volumes, further supported by favourable forex. QoQ decline was primarily on account of lower volume uptake in Russia.

-

Q4FY26 Russia revenues at ₹8.4 billion, growth of 28% YoY and decline of 21% QoQ.

FY26 Russia revenues at ₹34.8 billion, growth of 34% YoY.

In Q4FY26, YoY growth was supported by new launches, price increase in certain brands and favorable foreign exchange movements, while QoQ decline was primarily on account of lower sales volumes.

-

Q4FY26 Other Commonwealth of Independent States (CIS) countries and Romania revenues at ₹2.3 billion, decline of 4% YoY and QoQ.

6

FY26 CIS and Romania revenues at ₹9.1 billion, growth of 2% YoY.

In Q4FY26, decline was largely on account of weaker volumes, with sequential performance further impacted by lower prices in certain products.

-

Q4FY26 Rest of World (RoW) revenues at ₹7.3 billion, growth of 47% YoY and 23% QoQ.

FY26 RoW revenues at ₹23.7 billion, growth of 19% YoY.

Growth was largely on account of higher sales volumes from existing products across countries.

·

During Q4FY26, we launched 49 new products across countries, taking the total to 129 for FY26.

India

·

Q4FY26 revenues at ₹15.7 billion, growth of 20% YoY and decline of 2% QoQ.

FY26 revenues at ₹62.2 billion, growth of 16% YoY.

Growth was driven by revenues from new brand launches, including our innovation portfolio, price increases, higher volumes and contributions from recently acquired portfolios.

·

As per IQVIA data published for March 2026, our rank in the Indian Pharmaceutical Market (IPM) was at 9^th on a Moving Quarterly Total (MQT) and 10^th on a Moving Annual Total (MAT) basis. We continued to outperform the IPM, with secondary sales growth of 15.2% as compared to IPM growth of 11.6% on a MQT basis and 12.1% as compared to IPM growth of 9.9% on a MAT basis.

·

During the quarter, we launched ten new brands, taking the total to 28 for FY26.

Europe

·

Q4FY26 revenues at ₹14.5 billion, growth of 14% YoY and flat QoQ.

FY26 revenues at ₹55.5 billion, growth of 55% YoY. Excluding NRT, growth was at 14% YoY.

Contributions from the NRT portfolio, revenues from new generic product launches, higher volumes and favourable forex movement were moderated by pricing pressure in generics.

-

Q4FY26 NRT revenues at ₹7.0 billion, growth of 16% YoY and decline of 8% QoQ.

FY26 NRT revenues at ₹28.2 billion, versus ₹12.0 billion in FY25 for the period following its acquisition.

-

Q4FY26 Germany revenues at ₹3.8 billion, growth of 8% YoY and decline of 5% QoQ.

FY26 Germany revenues at ₹15.0 billion, growth of 16% YoY.

-

Q4FY26 UK revenues at ₹2.3 billion, growth of 6% YoY and 38% QoQ.

FY26 UK revenues at ₹7.3 billion, flat YoY.

-

Q4FY26 Rest of Europe revenues at ₹1.4 billion, growth of 35% YoY and 15% QoQ.

FY26 Rest of Europe revenues at ₹5.1 billion, growth of 37% YoY.

·

During the quarter, we launched seven new products in the region, taking the total to 38 for FY26.

Pharmaceutical Services and Active Ingredients (PSAI)

·

Q4FY26 revenues at ₹9.1 billion, decline of 5% YoY and growth of 14% QoQ.

FY26 revenues at ₹34.7 billion, growth of 3% YoY.

Decline in Q4FY26 was on account of lower volume uptake in the API business.

·

During the quarter, we filed 48 Drug Master Files (DMFs) globally, taking the total to 128 for FY26.

7

Income Statement Highlights:

Gross Margin

·

Q4FY26 at 44.8% (GG: 48.3%, PSAI: 19.9%), a decline of 1,074 basis points (bps) YoY and 881 bps QoQ.

FY26 at 52.8% (GG: 56.7%, PSAI: 17.2%), a decline of 573 bps YoY.

The YoY decline for the quarter was primarily on account of reduced sales of Lenalidomide, price erosion in North America and Europe Generics and a one-time SSA impact indicated earlier. FY26 was further impacted by one-time new Labour Code related provision in Q3FY26.

Excluding the one-offs related to SSA and new Labour Codes, gross margin for Q4FY26 at 48.0% (GG: 51.7%) and FY26 at 53.5% (GG: 57.5%).

Selling, General & Administrative (SG&A) Expenses

·

Q4FY26 at ₹27.8 billion, increase of 15% YoY and 3% QoQ.

As % to Revenues – Q4FY26: 36.9% | Q4FY25: 28.3% | Q3FY26: 30.8%.

FY26 at ₹106.8 billion, increase of 14% YoY.

As % to Revenues – FY26: 31.8% | FY25: 28.8%.

The YoY increase was driven by focused investments in our branded franchises, particularly the acquired consumer healthcare business in NRT and branded generics as well as a provision related to a potential VAT liability in one of our subsidiaries of ₹1.1 billion in Q4FY26. FY26 also was impacted by a similar provision in Q2FY26 and one-time new Labour Codes related provision in Q3FY26.

Excluding the impact of VAT liability and new Labor Codes provision, SG&A as a % of revenues excluding SSA impact : Q4FY26: 33.4% | FY26 : 30.6%.

Research & Development (R&D) Expenses

·

Q4FY26 at ₹5.5 billion, decrease of 25% YoY and 11% QoQ.

As % to Revenues – Q4FY26: 7.3% | Q4FY25: 8.5% | Q3FY26: 7.0%.

FY26 at ₹24.1 billion, decrease of 12% YoY.

As % to Revenues – FY26: 7.2% | FY25: 8.4%.

R&D expenditure was lower due to reduced development spends in Biosimilars, following completion of a large part of the investments related to Abatacept. R&D spends remain focused on complex generics including peptides and biosimilars. Q4FY26 was also impacted by charges related to certain discontinued CAR-T assets, while FY26 included the one-time new Labour Codes provision.

Excluding the impact of CAR-T related charges and new Labor Codes provision, R&D as a % of revenues excluding SSA impact for Q4FY26 : 6.8% | FY26 : 7.1%.

Impairment

·

Q4FY26 charge at ₹2.6 billion compared to ₹0.8 billion in Q4FY25.

FY26 charge at ₹3.5 billion compared to ₹1.7 billion in FY25.

Q4FY26 includes charges related to discontinuation of some R&D programs within the Chimeric Antigen Receptor T cell (CAR-T) therapy portfolio of ₹1.3 billion as well as a charge on account of discontinuation of trial of Eftilagimod Alfa, by parter Immutep of ₹0.9 billion.

8

Other Income

·

Q4FY26 income at ₹3.4 billion compared to ₹2.5 billion in Q4FY25.

FY26 income at ₹7.6 billion compared to ₹4.4 billion in FY25.

Q4FY26 includes income from divestment of certain non-core product related intangibles i.e., trademarks and marketing rights of ₹1.89 billion.

Net Finance Income/Expense

·

Q4FY26 income at ₹0.6 billion compared to ₹2.4 billion in Q4FY25.

FY26 income at ₹4.1 billion compared to ₹4.7 billion in FY25.

Net finance income in Q4FY26 was lower primarily on account of lower foreign exchange gain this quarter, in comparison to the corresponding quarter last year.

Profit before Tax (PBT)

·

Q4FY26 at ₹2.0 billion, decline of 90% YoY and 87% QoQ.

As % to Revenues – Q4FY26: 2.6% | Q4FY25: 23.6% | Q3FY26: 17.7%.

FY26 at ₹54.8 billion, decline of 29% YoY.

As % to Revenues – FY26: 16.3% | FY25: 23.6%.

Excluding the impact of SSA, VAT liability provision, costs related to discontinued CAR-T and impairment of Eftilagimod Alfa, new Labour Codes provision, PBT as a % of revenues : 12.5% in Q4FY26 | 19.0% in FY26.

Income Tax

·

Q4FY26 benefit at ₹0.2 billion. As % to PBT – Q4FY26: (10.8)% | Q4FY25: 20.9% | Q3FY26: 22.9%.

FY26 at ₹12.4 billion. As % to PBT – FY26: 22.5% | FY25: 25.4%.

The ETR was lower in Q4FY26 primarily due to a recognition of deferred tax assets on carry forward losses in one of our subsidiaries and a favourable jurisdictional mix for the quarter, in comparison to the same period in the previous year.

Profit attributable to Equity Holders of Parent Company

·

Q4FY26 at ₹2.2 billion, decline of 86% YoY and 82% QoQ.

As % to Revenues – Q4FY26: 2.9% | Q4FY25: 18.7% | Q3FY26: 13.9%.

FY26 at ₹42.9 billion, decline of 24% YoY.

As % to Revenues – FY26: 12.8% | FY25: 17.4%.

Diluted Earnings per Share (EPS)

·

Q4FY26 is ₹2.64.

FY26 is ₹51.42.

9

Other Financial Highlights:

EBITDA

·

Q4FY26 at ₹9.8 billion, decline of 60% YoY and 52% QoQ.

As % to Revenues – Q4FY26: 13.0% | Q4FY25: 29.1% | Q3FY26: 23.5%.

FY26 at ₹76.6 billion, decline of 17% YoY.

As % to Revenues – FY26: 22.8% | FY25: 28.3%.

Excluding the impact of SSA, provisions related to VAT liability and new Labour Codes and CAR-T related charges, EBITDA as a % of revenues excluding SSA impact: Q4FY26: 19.5% | FY26 : 24.7%.

Others:

·

Operating Working Capital: As on 31^st March 2026 at ₹144.3 billion | As on 31^st March 2025 at ₹126.0 billion

·

Capital Expenditure: Q4FY26 at ₹4.4 billion | FY26 at ₹23.0 billion.

·

Free Cash Flow (post acquisition related payout): Q4FY26 at ₹2.8 billion | FY26 at ₹16.9 billion.

·

Net Cash Surplus: As on 31^st March 2026 at ₹32.7 billion.

·

Net Debt to Equity: As on 31^st March 2026 is (0.09).

·

Return on Capital Employed (RoCE): FY26 stood at 15.8%.

Excluding the impact of SSA, provisions related to VAT liability and new Labour Codes, costs related to discontinued CAR-T and impairment of Eftilagimod Alfa, RoCE for FY26 at 17.5%.

10

About key metrics and non-GAAP Financial Measures

This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in this press release.

11

All amounts in millions, except EPS

Reconciliation of GAAP Measures to Non-GAAP Measures

Operating Working Capital

Particulars	As on 31^st Mar 2026			As on 31^st Mar 2025
	(₹)			(₹)
Inventories		76,531			71,085
Trade Receivables		101,219			90,420
Less:
Trade Payables		(33,411	)		(35,523	)
Operating Working Capital		144,339			125,982

Free Cash Flow

Particulars	Three months ended 31^st Mar 2026			Year ended 31^st Mar 2026
	(₹)			(₹)
Net cash generated from operating activities		17,259			70,281
Less:
Taxes		(1,614	)		(13,526	)
Investments in Property, Plant & Equipment and intangibles		(9,646	)		(36,715	)
Free Cash Flow before Acquisitions		5,999			20,040
Less:
Acquisitions related pay-out		(3,152	)		(3,152	)
Cash Flow		2,847			16,888

Net Cash Surplus and Debt to Equity

Particulars	As on 31^st Mar 2026
	(₹)
Cash and Cash Equivalents		15,368
Investments		83,141
Short-term Borrowings		(65,138	)
Long-term Borrowings (Current & Non-current)		(12,203	)
Less:
Restricted Cash Balance – Unclaimed Dividend and others		(109	)
Lease liabilities (Included in Short-term and Long-term Borrowings)		14,407
Equity Investments (Included in Investments)		(2,752	)
Net Cash Surplus		32,714
Equity		380,457
Net Debt/Equity		(0.09	)

12

Computation of RoCE

Particulars	As on 31^st Mar 2026
	(₹)
Profit before Tax		54,817
Less:
Interest and Investment Income (Excluding forex gain/loss)		(2,347	)
Earnings Before Interest and taxes [A]		52,469

Average Capital Employed [B]		332,856

Return on Capital Employed (A/B) (Ratio)		15.8	%

Computation of Capital Employed:

Particulars	As on
	Mar 31, 2026			Mar 31, 2025
Property Plant and Equipment		115,930			97,761
Intangibles		105,059			96,803
Goodwill		12,893			11,810
Investment in Equity Accounted Associates		5,673			4,811
Other Current Assets		36,256			30,142
Other Non-Current Assets		1,226			972
Inventories		76,531			71,085
Trade Receivables		101,219			90,420
Derivative Financial Instruments		(6,743	)		(729	)
Less:
Other Liabilities		53,702			48,788
Provisions		7,659			6,324
Trade payables		33,411			35,523
Operating Capital Employed		353,272			312,440
Average Capital Employed		332,856

Computation of EBITDA

Refer page no. 3 & 4.

13

Earnings Call Details

The management of the Company will host an Earnings call to discuss the Company’s financial performance and answer any questions from the participants.

Date: Tuesday, May 12, 2026

Time: 19:30 pm IST | 10:00 am ET

Conference Joining Information

Pre-register with the below link and join

https://drreddys.zoom.us/webinar/register/WN_DW56_eZ6SAGF8FWL6wa-EQ

Audio Link and Transcript will be available on the Company’s website: www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance.

For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025, our quarterly financial statements filed in Form 6-K with the US SEC for the quarter ended June 30, 2025, September 30, 2025, December 31, 2025 and our other filings with US SEC. The company assumes no obligation to update any information contained herein.

14

Exhibit 99.3

	Dr. Reddy’s Laboratories Ltd.
	8-2-337, Road No. 3, Banjara Hills,
	Hyderabad - 500 034, Telangana,
	India.
	CIN : L85195TG1984PLC004507

	Tel	: +91 40 4900 2900
	Fax	: +91 40 4900 2999
	Email	: mail@drreddys.com
	www.drreddys.com

DR. REDDY'S LABORATORIES LIMITED

Audited consolidated financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter and year ended 31 March 2026 prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB)

		All amounts in Indian Rupees millions
		Quarter ended									Year ended
		31.03.2026			31.12.2025			31.03.2025			31.03.2026			31.03.2025
S. No.	Particulars	(Audited)			(Unaudited)			(Audited)			(Audited)			(Audited)
1	Revenues		75,162			87,268			85,060			335,933			325,535
2	Cost of revenues		41,471			40,462			37,797			158,669			135,107
3	Gross profit (1 - 2)		33,691			46,806			47,263			177,264			190,428
4	Selling, general and administrative expenses		27,762			26,918			24,055			106,763			93,870
5	Research and development expenses		5,463			6,149			7,258			24,058			27,380
6	Impairment of non-current assets, net		2,586			271			768			3,519			1,693
7	Other income, net		(3,445	)		(770	)		(2,465	)		(7,627	)		(4,358	)
	Total operating expenses		32,366			32,568			29,616			126,713			118,585
8	Results from operating activities [(3) - (4 + 5 + 6 + 7)]		1,325			14,238			17,647			50,551			71,843
	Finance income		1,677			2,112			3,008			7,870			7,553
	Finance expense		(1,057	)		(944	)		(656	)		(3,738	)		(2,829	)
9	Finance (expense)/income, net		620			1,168			2,352			4,132			4,724
10	Share of profit of equity accounted investees, net of tax		46			23			55			134			217
11	Profit before tax (8 + 9 + 10)		1,991			15,429			20,054			54,817			76,784
12	Tax expense, net		(214	)		3,533			4,181			12,351			19,539
13	Profit for the period/year (11 -12)		2,205			11,896			15,873			42,466			57,245
	Attributable to:
	Equity holders of the parent company		2,201			12,098			15,939			42,850			56,544
	Non-controlling interests		4			(202	)		(66	)		(384	)		701

14	Earnings per equity share attributable to equity shareholders of parent
	Basic earnings per share of Re.1/- each		2.64			14.53			19.13			51.48			67.88
	Diluted earnings per share of Re.1/- each		2.64			14.52			19.11			51.42			67.78
			(Not annualised)			(Not annualised)			(Not annualised)

Segment information		All amounts in Indian Rupees millions
		Quarter ended						Year ended
		31.03.2026		31.12.2025		31.03.2025		31.03.2026		31.03.2025
Sl. No.	Particulars	(Audited)		(Unaudited)		(Audited)		(Audited)		(Audited)
	Segment wise revenue and results:
1	Segment revenue:
	a) Global Generics		65,802		79,113		75,365		299,033		289,552
	b) Pharmaceutical Services and Active Ingredients		11,075		9,675		11,675		42,043		43,235
	c) Others		236		137		132		2,127		2,137
	Total		77,113		88,925		87,172		343,203		334,924
	Less: Inter-segment revenues		1,951		1,657		2,112		7,270		9,389
	Total Revenues		75,162		87,268		85,060		335,933		325,535

2	Segment results:
	Gross profit from each segment
	a) Global Generics		31,809		45,375		44,707		169,698		179,606
	b) Pharmaceutical Services and Active Ingredients		1,817		1,385		2,518		5,984		9,157
	c) Others		65		46		38		1,582		1,665
	Total		33,691		46,806		47,263		177,264		190,428
	Less: Selling and other un-allocable expenditure, net of other income		31,700		31,377		27,209		122,447		113,644
	Total profit before tax		1,991		15,429		20,054		54,817		76,784

Global Generics segment includes operations of Biologics business. Inter-segment revenues represent sale from Pharmaceutical Services and Active Ingredients to Global Generics and Others at cost.

Segmental capital employed

As certain assets of the Company including manufacturing facilities, development facilities, treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

Consolidated statements of financial position

All amounts in Indian Rupees millions

	As at			As at
	31.03.2026			31.03.2025
Particulars	(Audited)			(Audited)
ASSETS
Current assets
Cash and cash equivalents		15,368			14,654
Other investments		72,446			43,254
Trade and other receivables		101,219			90,420
Inventories		76,531			71,085
Derivative financial instruments		155			557
Other current assets		36,256			30,142
Total current assets		301,975			250,112
Non-current assets
Property, plant and equipment		115,930			97,761
Goodwill		12,893			11,810
Other intangible assets		105,059			96,803
Investment in equity accounted investees		5,673			4,811
Other investments		10,695			10,391
Deferred tax assets		22,436			18,508
Tax assets		3,459			1,821
Other non-current assets		1,226			972
Total non-current assets		277,371			242,877
Total assets		579,346			492,989

LIABILITIES AND EQUITY
Current liabilities
Trade and other payables		33,411			35,523
Short-term borrowings		59,135			38,045
Long-term borrowings, current portion		6,003			857
Provisions		7,550			6,168
Tax liabilities		4,310			3,028
Derivative financial instruments		6,898			1,286
Other current liabilities		50,259			45,485
Total current liabilities		167,566			130,392
Non-current liabilities
Long-term borrowings		12,203			7,864
Deferred tax liabilities		15,568			14,108
Provisions		109			156
Other non-current liabilities		3,443			3,303
Total non-current liabilities		31,323			25,431
Total liabilities		198,889			155,823
Equity
Share capital		835			834
Treasury shares		(1,815	)		(2,264	)
Share premium		11,364			11,133
Share based payment reserve		1,684			1,642
Capital redemption reserve		173			173
Retained earnings		351,984			315,793
Other reserves		3,979			3,979
Other components of equity		8,859			2,098
Equity attributable to equity holders of the parent		377,063			333,388
Non-controlling interests		3,394			3,778
Total equity		380,457			337,166
Total liabilities and equity		579,346			492,989

Consolidated statements of cash flows

All amounts in Indian Rupees millions

	Year ended
	31.03.2026			31.03.2025
Particulars	(Audited)			(Audited)
Cash flows from/(used in) operating activities :
Profit for the year		42,466			57,245
Adjustments for:
Tax expense, net		12,351			19,539
Fair value changes and profit on sale of financial instruments measured at FVTPL*, net		(2,359	)		(3,554	)
Depreciation and amortization		20,605			17,058
Impairment of non-current assets, net		3,519			1,693
Allowance for credit losses (on trade receivables and other advances)		690			161
Profit on sale/disposal of assets, net		(2,547	)		(1,522	)
Share of profit of equity accounted investees		(134	)		(217	)
Foreign exchange (gain)/loss, net		(529	)		211
Interest (income)/expense, net		12			152
Inventories write-down		7,517			5,220
Equity settled share-based payment expense		326			424
Changes in operating assets and liabilities:
Trade and other receivables		(6,722	)		(10,283	)
Inventories		(8,601	)		(12,753	)
Trade and other payables		2,790			340
Other assets and other liabilities, net		897			(7,293	)
Cash generated from operations		70,281			66,421
Income tax paid, net		(13,526	)		(19,993	)
Net cash generated from operating activities		56,755			46,428
Cash flows from/(used in) investing activities :
Purchase of property, plant and equipment		(23,326	)		(27,504	)
Proceeds from sale of property, plant and equipment		309			512
Purchase of other intangible assets		(15,099	)		(6,894	)
Proceeds from sale of other intangible assets		1,401			732
Payment for acquisition of businesses		(3,152	)		(53,096	)
Investment in associates		(51	)		(317	)
Purchase of other investments (including bank deposits)		(46,718	)		(28,492	)
Proceeds from sale of other investments (including bank deposits)		19,602			53,610
Interest and dividend received		1,521			3,372
Net cash used in investing activities		(65,513	)		(58,077	)
Cash flows from/(used in) financing activities :
Proceeds from issuance of equity shares (including treasury shares)		397			193
Purchase of treasury shares		-			(1,389	)
Proceeds from short-term loans and borrowings, net		20,257			24,490
Repayment of long-term borrowings		(1	)		-
Proceeds from issuance of equity shares in subsidiary to Non-controlling interests		-			7,056
Payment of principal portion of lease liabilities		(1,263	)		(1,294	)
Dividend paid		(6,659	)		(6,662	)
Interest paid		(4,441	)		(3,483	)
Net cash from financing activities		8,290			18,911
Net increase/(decrease) in cash and cash equivalents		(468	)		7,262
Effect of exchange rate changes on cash and cash equivalents		1,243			224
Cash and cash equivalents at the beginning of the year		14,593			7,107
Cash and cash equivalents at the end of the year⁽¹⁾		15,368			14,593

*FVTPL (fair value through profit or loss)

⁽¹⁾Adjusted for bank-overdraft of Rs. 61 million for the year ended 31 March 2025.

Notes:

1

The above Statement of audited consolidated financial results of Dr. Reddy’s Laboratories Limited (the “parent company”), together with its subsidiaries (collectively, the “Company”), joint ventures and associates, have been prepared in accordance with recognition and measurement principles of IFRS as issued by the International Accounting Standards Board (IASB), and presented as per the format of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and were reviewed and recommended by Audit Committee and approved by the Board of Directors at their meetings held on 12 May 2026. The independent auditors have issued an unqualified report thereon.

2

During the quarter ended 31 March 2026, consequent to resolution of a Shelf Stock Adjustment claim arising from reduction in price of its generic product Lenalidomide in the United States, the Company has recorded an amount of Rs. 4,530 million (USD 50 million) as a reduction of “Revenue from sale of goods” in the Company's Global Generics Segment.

3

During the quarter ended 31 March 2026, the Company has decided to discontinue certain of its R&D programs associated with Chimeric Antigen Receptor T-cell (CAR-T) therapy portfolio in light of the current development status and recent clinical trial outcomes. Consequent to this decision, the Company has recognized a net loss of Rs. 1,350 million in the Company's Global Generic segment, comprising of:

a. Impairment of non-current assets of Rs. 1,291 million (i.e., towards Property, plant and equipment, Other Intangible assets and Right of use assets) and

b. Other development program related wind down cost under Selling, general and administrative expenses (“SG&A”) of Rs. 59 million.

4

During the quarter ended 31 March 2026, the Company has recorded an impairment loss of Rs.914 million (USD 10 million) consequent to discontinuation of the Phase III study in first line non-small cell lung cancer conducted by Immutep Limited following the results of the futility analysis.

5

During the year ended 31 March 2026, consequent to certain technical challenges in product development, the Company decided to discontinue development of conjugated estrogen at its site in Middleburgh, New York. Consequent to discontinuance of development, the Company recorded the following financial impacts in the Company's Global Generic segment, resulting in a net loss of Rs.47 million:

- Impairment loss of the entire carrying value of Rs.535 million for property, plant and equipment;

- Inventory related provisions of Rs.260 million;

- Other development program related wind down costs of Rs.129 million;

- Gain recognized under Other Income, net from the write back of liabilities no longer required of Rs.877 million.

6

"Impairment of non-current assets, net" for the year ended 31 March 2025 primarily includes:

a. Impairment of intangibles pertaining to acquisition from Mayne: -an amount of Rs.907 million towards Haloette® (a generic equivalent to Nuvaring®), a product-related intangible, due to constraints on procurement of the underlying product from its contract manufacturer, resulting in a lower recoverable value compared to the carrying value. -an amount of Rs.270 million pertaining to impairment of certain product related intangibles, due to adverse market conditions resulting in lower recoverable value compared to the carrying value.

b. Other impairments:

During the year ended 31 March 2025, consequent to adverse market conditions with respect to certain product related intangibles, the Company assessed the recoverable value of certain products and recognized impairment loss of Rs.288 million pertaining to products forming part of the Company’s business in India and Europe.

The above impairment charge pertains to Company's Global Generics segment.

7

“Other income, net” includes:

a. Rs. 1,400 million recognised pursuant to settlement of product related litigations representing payment for avoided litigation costs by the Company and its affiliates in the United States and the United Kingdom during the year ended 31 March 2026.

b. Gain on sale of non-current assets, net amounting to Rs. 1,890 million towards divestment of certain product related intangibles i.e., trademarks during the quarter ended 31 March 2026.

8

“Other income, net” for the year ended 31 March 2025 includes cumulative amount of foreign exchange gain of Rs. 1,551 million, reclassed from the foreign currency translation reserve to the Other income, net, and a loss of Rs. 52 million due to turnaround fees paid upon divestment of the membership interest in the subsidiary “Dr. Reddy’s Laboratories Louisiana LLC” to Jaguar labs Holdings LLC during March 2025.

This transaction pertains to the Company's Global Generics segment.

9

The Company received a field tax audit report from the Federal Tax Service authority in respect of one of its foreign subsidiaries for the period from January 2020 to December 2022. The report concluded that certain services were subject to value-added tax (VAT). The Company filed objections to the findings, and a revised audit report was issued on 15 September 2025 with a reduced VAT liability. Based on its best estimate, the Company had recorded a provision of Rs. 695 million under SG&A during the quarter ended 30 September 2025.

The Company continued to defend its position and submitted further objections, asserting that the specified services should not be subject to VAT. On 23 March 2026, the Company received the final order from the Federal Tax Service authorities, pursuant to which the originally proposed VAT liability was substantially reduced. Based on the final order, an additional provision of Rs. 1,141 million, including applicable interest and penalties, was recognized for the periods covered under audit as well as subsequent period from calendar year 2023 through 31 March 2026.

This additional provision was recorded under SG&A during the quarter ended 31 March 2026. The Company believes that the likelihood of any further liability on account of this field tax audit is not probable.

This transaction pertains to the Company’s Global Generics segment.

10

The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code 2020 (collectively referred to as the “New Labour Codes”). The New Labour Codes are effective from 21 November 2025 and introduce changes, among other things, setting a uniform definition of wages. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs.1,170 million towards employee benefits during the year ended 31 March 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to and the impact of these will be accounted in accordance with applicable accounting standards.

11

The Company received an anonymous complaint in September 2020, alleging that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of U.S. anti-corruption laws, specifically the U.S. Foreign Corrupt Practices Act. The Company disclosed the matter to the U.S. Department of Justice (“DOJ”), Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India. The Company engaged a U.S. law firm to conduct the investigation at the instruction of a committee of the Company’s Board of Directors. On 6 July 2021 the Company received a subpoena from the SEC for the production of related documents, which were provided to the SEC.

The Company engaged with the SEC and DOJ, including through submissions and presentations regarding the initial complaint and additional complaints relating to other markets, and in relation to its Global Compliance Framework, which included enhancement initiatives undertaken by the Company, and the Company complied with its listing obligations as it relates to updating the regulatory agencies. On 23 February 2026 the Company received a letter from the SEC stating that, based on the information available to it, the SEC has concluded its investigation and does not intend to recommend any enforcement action against the Company at this time. On 5 March 2026, the Company received a letter from the DOJ stating that, based on the information available to it, the DOJ has closed its inquiry.

12

The Company considered the on-going uncertainties relating to geo-political conflicts (including Russia and Ukraine) in assessing the recoverability of receivables, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgments, estimates and assumptions, the Company expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.

13

The Board of Directors, at their meeting held on 12 May 2026, have recommended a final dividend of Rs.8 per share subject to approval of shareholders.

14

The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year. Also the figures up to the end of third quarter were only reviewed and not subjected to audit.

	By order of the Board
	For Dr. Reddy's Laboratories Limited


Place: Hyderabad	G V Prasad
Date: 12 May 2026	Co-Chairman & Managing Director
	DIN: 00057433

Exhibit 99.4

THE SKYVIEW 10

18th Floor, “NORTH LOBBY”

Survey No. 83/1, Raidurgam

Hyderabad - 500 032, India

Tel: +91 40 6141 6000

Independent Auditor’s Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors of

Dr. Reddy’s Laboratories Limited

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying ‘Statement of Audited Consolidated Financial Results for the quarter and year ended 31 March 2026 (the “Statement”)’ of Dr. Reddy’s Laboratories Limited (the “Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as “the Group”), its associates and joint ventures attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements of the subsidiaries referred to in the Other Matters paragraph below, the Statement:

i.

includes the results of the following entities:

Holding Company

Dr. Reddy’s Laboratories Limited

Subsidiaries

1.

Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.

2.

Aurigene Oncology Limited (Formerly, Aurigene Discovery Technologies Limited)

3.

Aurigene Pharmaceutical Services Limited

4.

beta Institut gemeinnützige GmbH

5.

betapharm Arzneimittel GmbH

6.

Cheminor Investments Limited

7.

Dr. Reddy’s Farmaceutica Do Brasil Ltda.

8.

Dr. Reddy’s Laboratories (EU) Limited

9.

Dr. Reddy’s Laboratories (Proprietary) Limited

10.

Dr. Reddy’s Laboratories (UK) Limited

11.

Dr. Reddy’s Laboratories Canada, Inc.

12.

Dr. Reddy’s Laboratories Chile SPA

13.

Dr. Reddy’s Laboratories Inc.

14.

Dr. Reddy’s Laboratories Japan KK

15.

Dr. Reddy’s Laboratories Kazakhstan LLP

16.

Dr. Reddy’s Laboratories Malaysia Sdn. Bhd.

17.

Dr. Reddy’s Laboratories New York, LLC

18.

Dr. Reddy’s Laboratories Philippines Inc.

19.

Dr. Reddy’s Laboratories Romania SRL

20.

Dr. Reddy’s Laboratories SA

21.

Dr. Reddy’s Laboratories Taiwan Limited

22.

Dr. Reddy’s Laboratories (Thailand) Limited

23.

Dr. Reddy’s Laboratories LLC, Ukraine

24.

Dr. Reddy’s New Zealand Limited

S.R. Batliboi & Associates LLP, a Limited Liability Partnership with LLP Identity No. AAB-4295

Regd. Office: 22, Camac Street, Block ‘B’, 3rd Floor, Kolkata-700 016

25.

Dr. Reddy’s SRL

26.

Dr. Reddy’s Bio-Sciences Limited

27.

Dr. Reddy’s Laboratories (Australia) Pty. Limited

28.

Dr. Reddy’s Laboratories SAS

29.

Dr. Reddy’s Netherlands B.V. (Formally Dr. Reddy’s Research and Development B.V.)

30.

Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited

31.

DRL Impex Limited

32.

Dr. Reddy’s Formulations Limited

33.

Idea2Enterprises (India) Pvt. Limited

34.

Imperial Owners and Land Possessions Private Limited (Formerly, Imperial Credit Private Limited, till August 05, 2025)

35.

Industrias Quimicas Falcon de Mexico, S.A. de CV

36.

Lacock Holdings Limited

37.

Dr. Reddy’s Laboratories LLC, Russia

38.

Promius Pharma LLC

39.

Reddy Holding GmbH

40.

Reddy Netherlands B.V.

41.

Reddy Pharma Iberia SAU

42.

Reddy Pharma Italia S.R.L.

43.

Reddy Pharma SAS

44.

Svaas Wellness Limited

45.

Nimbus Health GmbH

46.

Dr. Reddy’s Laboratories Jamaica Limited

47.

Dr. Reddy’s and Nestle Health Science Limited (Formerly, Dr. Reddy’s Nutraceuticals Limited)

48.

Northstar Switzerland SARL

49.

North Star OpCo Limited

50.

North Star Sweden AB

51.

Dr. Reddy's Denmark ApS

52.

Dr. Reddy’s Finland Oy

53.

Dr. Reddy’s Laboratories (Vietnam) Company Limited (incorporated on May 09, 2025)

Associates

1.

O2 Renewabale Energy IX Private Limited

2.

Clean Renewable Energy KK 2A Private Limited

Joint Venture

1.

DRES Energy Private Limited

2.

Kunshan Rotam Reddy Pharmaceutical Co. Limited (including Kunshan Rotam Reddy Medicine Company Limited)

Other Consolidating Entities

1.

Dr Reddy’s Employees ESOS Trust

2.

Cheminors Employees Welfare Trust

3.

Dr. Reddy’s Research Foundation

ii.

are presented in accordance with the requirements of the Listing Regulations in this regard; and

iii.

gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Consolidated Financial Results” section of our report. We are independent of the Group, its associates and joint ventures in accordance with the ‘Code of Ethics’ issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matters” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management’s Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associates and joint ventures in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of their respective companies and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for assessing the ability of their respective companies to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are also responsible for overseeing the financial reporting process of their respective companies.

Auditor’s Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

·

Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

·

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act,
we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating
effectiveness of such controls.

·

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

·

Conclude on the appropriateness of the Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group and its associates and joint ventures to cease to continue as a going concern.

·

Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

·

Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates and joint ventures of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Master Circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

1.

The accompanying Statement includes the audited financial results/statements and other financial information, in respect of one subsidiary, whose financial results/statements include total assets of Rs. 31,687 Mn as at March 31, 2026, total revenues of Rs. 8,836 Mn and Rs. 35,102 Mn, total net profit after tax of Rs. 487 Mn and Rs. 797 Mn, total comprehensive income of Rs. 487 Mn and Rs. 797 Mn, for the quarter and the year ended on that date respectively, and net cash inflows of Rs. 803 Mn for the year ended March 31, 2026, as considered in the Statement which have been audited by its independent auditor. The independent auditor’s report on the financial results of this entity has been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the reports of such auditor and the procedures performed by us as stated in paragraph above.

2.

The accompanying Statement includes unaudited financial results and other unaudited financial information in respect of two associates and two joint ventures, whose financial results includes the Group’s share of net profit of Rs. 46 Mn and Rs. 134 Mn and Group’s share of total comprehensive income of Rs. 46 Mn and Rs. 134 Mn for the quarter and year ended March 31, 2026 respectively, as considered in the Statement whose financial results/statements and other financial information have not been audited by their auditors. These unaudited financial results have been approved and furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these joint ventures and associates, is based solely on such unaudited financial results. In our opinion and according to the information and explanations given to us by the Management, these financial results are not material to the Group.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the report of the other auditor and the financial results/financial information certified by the Management.

3.

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004

per Shankar Srinivasan

Partner

Membership No.: 213271

UDIN: 26213271FALXKG8081

Place: Hyderabad

Date: May 12, 2026

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,

India.

CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900

Fax :+91 40 4900 2999

Email :mail@drreddys.com

www.drreddys.com

DR. REDDY'S LABORATORIES LIMITED

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

All amounts in Indian Rupees millions

		Quarter ended									Year ended
		31.03.2026			31.12.2025			31.03.2025			31.03.2026			31.03.2025
Sl. No.	Particulars	(Audited)			(Unaudited)			(Audited)			(Audited)			(Audited)

1	Revenue from operations
	a) Sales		72,957			84,204			82,105			326,213			316,320
	b) License fees and service income		2,205			3,066			2,955			9,720			9,215
	c) Other operating income		302			264			224			1,069			904
	Total revenue from operations		75,464			87,534			85,284			337,002			326,439
2	Other income		4,754			2,688			5,221			13,584			10,973
3	Total income (1 + 2)		80,218			90,222			90,505			350,586			337,412
4	Expenses
	a) Cost of materials consumed		11,986			18,255			17,165			65,012			56,835
	b) Purchase of stock-in-trade		16,577			15,421			11,275			61,616			48,411
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		3,564			(2,723	)		60			(4,236	)		(5,447	)
	d) Employee benefits expense		14,468			15,885			14,006			59,909			55,800
	e) Depreciation and amortisation expense		5,571			5,210			4,547			20,588			17,037
	f) Impairment of non-current assets, net		2,575			270			768			3,518			1,693
	g) Finance costs		1,057			944			656			3,738			2,829
	h) Other expenses		22,469			21,551			22,031			86,648			83,676
	Total expenses		78,267			74,813			70,508			296,793			260,834
5	Profit before tax and before share of equity accounted investees(3 - 4)		1,951			15,409			19,997			53,793			76,578
6	Share of profit of equity accounted investees, net of tax		46			23			55			134			217
7	Profit before tax (5+6)		1,997			15,432			20,052			53,927			76,795
8	Tax expense/(benefit):
	a) Current tax		(237	)		2,074			4,323			13,945			22,581
	b) Deferred tax		21			1,462			(138	)		(1,594	)		(3,038	)
9	Net profit after taxes and share of profit of associates (7 - 8)		2,213			11,896			15,867			41,576			57,252
10	Net profit after taxes attributable to
	a) Equity shareholders of the parent company		2,209			12,099			15,933			41,960			56,551
	b) Non-controlling interests		4			(203	)		(66	)		(384	)		701
11	Other comprehensive income/(loss)
	a) (i) Items that will not be reclassified subsequently to profit or loss		168			(16	)		(117	)		143			(293	)
	(ii) Income tax relating to items that will not be reclassified to profit or loss		(56	)		-			24			(56	)		24
	b) (i) Items that will be reclassified subsequently to profit or loss		2,167			1,810			1,425			6,916			2,376
	(ii) Income tax relating to items that will be reclassified to profit or loss		179			(24	)		(238	)		392			(58	)
	Total other comprehensive income/(loss)		2,458			1,770			1,094			7,395			2,049
	Total comprehensive income (9 + 11)		4,671			13,666			16,961			48,971			59,301
12	Total comprehensive income attributable to
	a) Equity shareholders of the parent company		4,667			13,869			17,027			49,355			58,600
	b) Non-controlling interest		4			(203	)		(66	)		(384	)		701
13	Paid-up equity share capital (face value Re. 1/- each)		835			835			834			835			834
14	Other equity											378,080			334,662
15	Earnings per equity share attributable to equity shareholders of parent(face value Re. 1/- each)
	Basic		2.65			14.53			19.12			50.41			67.89
	Diluted		2.65			14.52			19.10			50.35			67.79
			(Not annualised)			(Not annualised)			(Not annualised)

See accompanying notes to the financial results

DR. REDDY'S LABORATORIES LIMITED

Segment information

All amounts in Indian Rupees millions

		Quarter ended						Year ended
		31.03.2026		31.12.2025		31.03.2025		31.03.2026		31.03.2025
Sl. No.	Particulars	(Audited)		(Unaudited)		(Audited)		(Audited)		(Audited)
	Segment wise revenue and results:
1	Segment revenue :
	a) Global Generics		65,925		79,568		75,432		299,460		289,810
	b) Pharmaceutical Services and Active Ingredients		11,247		9,472		11,819		42,672		43,868
	c) Others		243		151		145		2,140		2,150
	Total		77,415		89,191		87,396		344,272		335,828
	Less: Inter-segment revenue		1,951		1,657		2,112		7,270		9,389
	Total revenue from operations		75,464		87,534		85,284		337,002		326,439
2	Segment results:
	Gross profit from each segment
	a) Global Generics		31,768		45,411		44,707		169,696		179,606
	b) Pharmaceutical Services and Active Ingredients		1,849		1,360		2,526		6,002		9,178
	c) Others		74		43		40		1,581		1,665
	Total		33,692		46,814		47,273		177,280		190,449
	Less: Selling and other un-allocable expenditure/(income), net		31,694		31,382		27,221		123,352		113,654
	Total profit before tax		1,997		15,432		20,052		53,927		76,795

Global Generics includes operations of Biologics business. Inter-segment revenue represents sales from Pharmaceutical Services and Active Ingredients to Global Generics and Others at cost.

Segmental capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

DR. REDDY'S LABORATORIES LIMITED

Consolidated Balance Sheet

All amounts in Indian Rupees millions

	As at		As at
	31.03.2026		31.03.2025
Particulars	(Audited)		(Audited)
ASSETS
Non-current assets
Property, plant and equipment		100,778		72,984
Capital work-in-progress		14,602		23,994
Goodwill		14,797		13,139
Other intangible assets		105,058		96,141
Intangible assets under development		-		662
Investment in equity accounted investees		5,673		4,811
Financial assets
Investments		8,942		2,393
Other financial assets		2,917		8,875
Deferred tax assets, net		22,190		18,325
Tax assets, net		3,503		1,821
Other non-current assets		981		940
Total non-current assets		279,441		244,085

Current assets
Inventories		76,534		71,085
Financial assets
Investments		38,233		33,307
Trade receivables		101,234		90,420
Derivative financial instruments		155		557
Cash and cash equivalents		15,368		14,654
Other bank balances		18,119		9,948
Other financial assets		22,255		3,142
Other current assets		29,895		27,068
Total current assets		301,793		250,181
TOTAL ASSETS		581,234		494,266

EQUITY AND LIABILITIES
Equity
Equity share capital		835		834
Other equity		378,080		334,662
Equity attributable to equity shareholders of the parent company		378,915		335,496
Non-Controlling interests		3,394		3,778
Total equity		382,309		339,274
Liabilities
Non-current liabilities
Financial liabilities
Borrowings		-		3,800
Lease liabilities		12,203		4,064
Other financial liabilities		432		198
Provisions		338		298
Deferred tax liabilities, net		15,467		14,038
Other non-current liabilities		3,011		2,256
Total non-current liabilities		31,451		24,654
Current liabilities
Financial liabilities
Borrowings		62,935		38,045
Lease liabilities		2,203		857
Trade payables
Total outstanding dues of micro enterprises and small enterprises		334		210
Total outstanding dues of creditors other than micro enterprises and small enterprises		30,045		26,268
Derivative financial instruments		6,898		1,286
Other financial liabilities		40,085		39,698
Other current liabilities		11,921		13,190
Tax Liabilities, net		4,353		3,028
Provisions		8,700		7,756
Total current liabilities		167,474		130,338
TOTAL EQUITY AND LIABILITIES		581,234		494,266

DR. REDDY'S LABORATORIES LIMITED

Consolidated statement of cashflows

All amounts in Indian Rupees millions

	Year ended			Year ended
	31.03.2026			31.03.2025
Particulars	(Audited)			(Audited)
Cash flows from/(used in) operating activities :
Profit before tax		53,927			76,795
Adjustments for:
Fair value changes and profit on sale of financial instruments measured at FVTPL*, net		(2,359	)		(3,554	)
Depreciation and amortisation expense		20,588			17,037
Impairment of non-current assets, net		3,518			1,693
Allowance for credit losses (on trade receivables and other advances)		690			161
Profit on sale/disposal of assets, net		(2,547	)		(1,512	)
Share of profit of equity accounted investees		(134	)		(217	)
Unrealized exchange loss/(gain), net		(529	)		211
Interest income		(3,726	)		(2,677	)
Finance costs		3,738			2,829
Equity settled share-based payment expense		326			424
Inventories write-down		7,517			5,220
Changes in operating assets and liabilities:
Trade receivables		(6,722	)		(10,283	)
Inventories		(8,601	)		(12,753	)
Trade payables		2,790			340
Other assets and other liabilities, net		1,787			(7,293	)
Cash generated from operations		70,263			66,421
Income tax paid, net		(13,526	)		(19,993	)
Net cash from operating activities		56,737			46,428
Cash flows from/(used in) investing activities :
Purchase of property, plant and equipment		(23,306	)		(27,504	)
Proceeds from sale of property, plant and equipment		309			512
Purchase of other intangible assets		(15,099	)		(6,894	)
Proceeds from sale of other intangible assets		1,401			732
Investment in associates		(51	)		(317	)
Purchase of investments (including bank deposits)		(46,718	)		(28,492	)
Proceeds from sale of investments (including bank deposits)		19,602			53,610
Payment for acquisition of businesses		(3,152	)		(53,096	)
Interest and dividend received		1,521			3,372
Net cash used in investing activities		(65,493	)		(58,077	)
Cash flows from/(used in) financing activities :
Proceeds from issuance of equity shares (including treasury shares)		397			193
Purchase of treasury shares		-			(1,389	)
Proceeds from short-term borrowings, net		20,257			24,490
Repayment of long-term loans and borrowings		(1	)		-
Proceeds from issuance of equity shares in subsidiary to Non controlling interest		-			7,056
Payment of principal portion of lease liabilities		(1,263	)		(1,294	)
Dividend paid		(6,659	)		(6,662	)
Interest paid		(4,441	)		(3,483	)
Net cash from financing activities		8,290			18,911
Net increase/(decrease) in cash and cash equivalents		(466	)		7,262
Effect of exchange rate changes on cash and cash equivalents		1,241			224
Cash and cash equivalents at the beginning of the year		14,593			7,107
Cash and cash equivalents at the end of the year⁽¹⁾		15,368			14,593

*FVTPL (fair value through profit or loss)

⁽¹⁾Adjusted for bank-overdraft of Rs. Nil and Rs. 61 million for the year ended 31 March 2026 and 31 March 2025 respectively.

DR. REDDY'S LABORATORIES LIMITED

Notes:

1	The above statement of audited consolidated financial results of Dr. Reddy's Laboratories Limited ("the parent company"), together with its subsidiaries (collectively, "the Company") joint ventures and associates, have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act,2013 ("the Act") read with relevant rules issues thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by Audit Committee and approved by the Board of Directors at their meetings held on 12 May 2026. The Statutory Auditors have issued an unqualified report thereon.

2	During the quarter ended 31 March 2026, consequent to resolution of a Shelf Stock Adjustment claim arising from reduction in price of its generic product Lenalidomide in the United States, the Company has recorded an amount of Rs. 4,530 million (USD 50 million) as a reduction of “Revenue from operations” in the Company's Global Generics Segment.

3	During the quarter ended 31 March 2026, the Company has decided to discontinue certain of its R&D programs associated with Chimeric Antigen Receptor T-cell (CAR-T) therapy portfolio in light of the current development status and recent clinical trial outcomes. Consequent to this decision, the Company has recognized a net loss of Rs. 1,350 million in the Company's Global Generic segment, comprising of: a. Impairment of non-current assets of Rs. 1,291 million (i.e., towards Property, plant and equipment, Other Intangible assets and Right of use assets) and b. Other development program related wind down cost under "Other expenses" of Rs. 59 million.

4	During the quarter ended 31 March 2026, the Company has recorded an impairment loss of Rs.914 million (USD 10 million) consequent to discontinuation of the Phase III study in first line non-small cell lung cancer conducted by Immutep Limited following the results of the futility analysis.

5	During the year ended 31 March 2026, consequent to certain technical challenges in product development, the Company decided to discontinue development of conjugated estrogen at its site in Middleburgh, New York.Consequent to discontinuance of development, the Company recorded the following financial impacts in the Company's Global Generic segment, resulting in a net loss of Rs.934 million in the consolidated financial results - Impairment loss of the entire carrying value of Rs.545 million for property, plant and equipment; - Inventory related provisions of Rs.260 million; - Other development program related wind down costs of Rs.129 million;

6	"Impairment of non-current assets, net" for the ycar ended 31 March 2025 primarily includes: a. Impairment of intangibles pertaining to acquisition from Mayne: -an amount of Rs.907 million towards Haloette® (a generic equivalent to Nuvaring), a product-related intangible, due to constraints on procurement of the underlying product from its contract manufacturer, resulting in a lower recoverable value compared to the carrying value. -an amount of Rs.270 million pertaining to impairment of certain product related intangibles, due to adverse market conditions resulting in lower recovcrable value compared to the carrying value. b. Other impairments: During the year ended 31 March 2025, consequent to adverse market conditions with respect to certian product related intangibles, the company assessed the recoverable value of certain products and recognised impairment loss of Rs. 288 million pertaining to products forming part of the Company's Global Generic business in India and Europe.

7	Other income includes: a. Rs. 1,400 million recognised prusuant to settlement of product related litigations representing payment for avoided litigation costs by the Company and its affiliates in the United States and the United Kingdom during the year ended 31 March 2026. b. Gain on sale of non-current assets, net amounting to Rs. 1,890 million towards divestment of certain product related intangibles i.e., trademarks during the quarter ended 31 March 2026.

8	"Other income" for the year ended 31 March 2025 includes cumulative amount of foreign exchange gain of Rs.1,551 million, reclassified from the foreign currency translation reserve upon divestment of the membership interest in the subsidiary “Dr. Reddy’s Laboratories Louisiana LLC”. This transaction pertains to the Company's Global Generics segment.
9	The Company received a field tax audit report from the Federal Tax Service authority in respect of one of its foreign subsidiaries for the period from January 2020 to December 2022. The report concluded that certain services were subject to value-added tax (VAT). The Company filed objections to the findings, and a revised audit report was issued on 15 September 2025 with a reduced VAT liability. Based on its best estimate, the Company had recorded a provision of Rs. 695 million under “Other Expenses” during the quarter ended 30 September 2025. The Company continued to defend its position and submitted further objections, asserting that the specified services should not be subject to VAT. On 23 March 2026, the Company received the final order from the Federal Tax Service authorities, pursuant to which the originally proposed VAT liability was substantially reduced. Based on the final order, an additional provision of Rs. 1,141 million, including applicable interest and penalties, was recognized for the periods covered under audit as well as subsequent period from calendar year 2023 through 31 March 2026. This additional provision was recorded under “Other Expenses” during the quarter ended 31 March 2026. The Company believes that the likelihood of any further liability on account of this field tax audit is not probable. This transaction pertains to the Company’s Global Generics segment.

10	The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code 2020 (collectively referred to as the “New Labour Codes”). The New Labour Codes are effective from 21 November 2025 and introduce changes that include, among other things, setting a uniform definition of wages.The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs.1,170 million towards employee benefits during the year ended 31 March 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to and the impact of these will be accounted in accordance with applicable accounting standards.

DR. REDDY'S LABORATORIES LIMITED

11	The Company received an anonymous complaint in September 2020, alleging that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of U.S. anti-corruption laws, specifically the U.S. Foreign Corrupt Practices Act. The Company disclosed the matter to the U.S. Department of Justice (“DOJ”), Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India. The Company engaged a U.S. law firm to conduct the investigation at the instruction of a committee of the Company’s Board of Directors. On 06 July 2021 the Company received a subpoena from the SEC for the production of related documents, which were provided to the SEC. The Company engaged with the SEC and DOJ, including through submissions and presentations regarding the initial complaint and additional complaints relating to other markets, and in relation to its Global Compliance Framework, which included enhancement initiatives undertaken by the Company, and the Company complied with its listing obligations as it relates to updating the regulatory agencies. On February 23 2026 the Company received a letter from the SEC stating that, based on the information available to it, the SEC has concluded its investigation and does not intend to recommend any enforcement action against the Company at this time. On 05 March 2026, the Company received a letter from the DOJ stating that, based on the information available to it, the DOJ has closed its inquiry.

12	The Company considered the on-going uncertainties relating to geo-political conflicts (including Russia and Ukraine) in assessing the recoverability of receivables, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgments, estimates and assumptions, the Company expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.

13	The Board of Directors, at their meeting held on 12 May 2026, have recommended a final dividend of Rs.8 per share subject to approval of shareholders.

14	The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year. Also the figures upto the end of third quarter were only reviewed and not subjected to audit.

	By order of the Board
	For Dr. Reddy's Laboratories Limited


Place: Hyderabad	G V Prasad
Date: 12 May 2026	Co-Chairman & Managing Director
	DIN: 00057433

Exhibit 99.5

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana,

India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: mail@drreddys.com

www.drreddys.com

May 12, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Subject: Decaration under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs/Madam,

Pursuant to the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, I, M V Narasimham, Chief Financial Officer of the Company hereby declare that, the Statutory Auditors of the Company, M/s. S R Batliboi & Associates LLP, Chartered Accountants (Firm Registration No. 101049W/E300004), have issued an Audit Report with unmodified opinion on the annual Audited Financial Results of the Company (Standalone & Consolidated) for year ended on March 31, 2026.

Request you to kindly take this declaration on your records.

M V Narasimham

Chief Financial Officer

Date: 12.05.2026

Place: Hyderabad

THE SKYVIEW 10

18th Floor, “NORTH LOBBY”

Survey No. 83/1, Raidurgam

Hyderabad - 500 032, India

Tel : +91 40 6141 6000

Independent Auditor’s Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors of

Dr. Reddy’s Laboratories Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying “Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2026” (“Statement”) of Dr. Reddy’s Laboratories Limited (the “Company”), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

i.

is presented in accordance with the requirements of the Listing Regulations in this regard; and

ii.

gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive loss and other financial information of the Company for the quarter March 31, 2026 and net profit and other comprehensive loss and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Standalone Financial Results” section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management’s Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net loss and other comprehensive loss of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

S.R. Batliboi & Associates LLP, a Limited Liability Partnership with LLP Identity No. AAB-4295

Regd. Office : 22, Camac Street, Block ‘B’, 3rd Floor, Kolkata-700 016

In preparing the Statement, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company’s financial reporting process.

Auditor’s Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

·

Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

·

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

·

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

·

Conclude on the appropriateness of the Board of Directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.

·

Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004

per Shankar Srinivasan

Partner

Membership No.: 213271

UDIN: 26213271HWYRVT2241

Place: Hyderabad

Date: May 12, 2026

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,

India.

CIN : L85195TG1984PLC004507

Tel :+91 40 4900 2900

Fax :+91 40 4900 2999

Email :mail@drreddys.com

www.drreddys.com

DR. REDDY’S LABORATORIES LIMITED

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

All amounts in Indian Rupees millions

		Quarter ended									Year ended
		31.03.2026			31.12.2025			31.03.2025			31.03.2026			31.03.2025
Sl. No.	Particulars	(Audited)			(Unaudited)			(Audited)			(Audited)			(Audited)

1	Revenue from operations
	a) Sales		37,197			40,718			54,063			201,022			218,448
	b) License fees and service income		829			1,946			1,400			3,584			12,020
	c) Other operating income		194			163			166			722			686
	Total revenue from operations		38,220			42,827			55,629			205,328			231,154
2	Other income		5,672			3,603			4,144			16,896			10,034
	Total income (1 + 2)		43,892			46,430			59,773			222,224			241,188
3	Expenses
	a) Cost of materials consumed		11,212			10,668			9,426			43,325			37,997
	b) Purchase of stock-in-trade		4,790			7,692			5,347			26,358			24,399
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		1,162			(1,315	)		822			(2,305	)		(1,739	)
	d) Employee benefits expense		8,345			9,602			7,971			35,499			32,875
	e) Depreciation and amortisation expense		3,185			3,143			2,645			12,074			10,394
	f) Impairment of non current assets, net		1,211			157			1,036			1,405			1,036
	g) Finance costs		543			414			311			1,483			1,099
	h) Other expenses		16,499			15,027			16,597			61,872			62,768
	Total expenses		46,947			45,388			44,155			179,711			168,829
4	Profit/(loss) before tax (1 + 2 - 3)		(3,055	)		1,042			15,618			42,513			72,359
5	Tax expense/(benefit)
	a) Current tax		(1,147	)		130			3,643			9,177			17,905
	b) Deferred tax		286			6			(32	)		1,139			960
6	Net profit/(loss) for the period/year (4 - 5)		(2,194	)		906			12,007			32,197			53,494
7	Other comprehensive income
	a) (i) Items that will not be reclassified to profit or loss		134			-			(103	)		134			(103	)
	(ii) Income tax relating to items that will not be reclassified to profit or loss		(34	)		-			26			(34	)		26
	b) (i) Items that will be reclassified to profit or loss		(854	)		94			1,046			(1,698	)		234
	(ii) Income tax relating to items that will be reclassified to profit or loss		214			(24	)		(263	)		427			(59	)
	Total other comprehensive income/(loss)		(540	)		70			706			(1,171	)		98
8	Total comprehensive income/(loss) (6 + 7)		(2,734	)		976			12,713			31,026			53,592
9	Paid-up equity share capital (face value Re. 1/- each)		835			835			834			835			834
10	Other equity											312,821			287,732
11	Earnings per equity share (face value Re. 1/- each)
	Basic		(2.63	)		1.09			14.41			38.68			64.22
	Diluted		(2.63	)		1.09			14.39			38.64			64.13
			(Not annualised)			(Not annualised)			(Not annualised)

See accompanying notes to the financial results.

DR. REDDY’S LABORATORIES LIMITED

Segment information

All amounts in Indian Rupees millions

		Quarter ended									Year ended
		31.03.2026			31.12.2025			31.03.2025			31.03.2026			31.03.2025
Sl. No.	Particulars	(Audited)			(Unaudited)			(Audited)			(Audited)			(Audited)
	Segment wise revenue and results
1	Segment revenue
	a) Global Generics		31,487			38,129			48,287			182,027			204,602
	b) Pharmaceutical Services and Active Ingredients		8,350			6,257			9,140			29,750			33,904
	c) Others		130			57			45			464			1,410
	Total		39,967			44,443			57,472			212,241			239,916

	Less: Inter-segment revenue		1,747			1,616			1,843			6,913			8,762
	Total revenue from operations		38,220			42,827			55,629			205,328			231,154

2	Segment results
	Profit/(loss) before tax and interest from each segment
	a) Global Generics		(3,141	)		2,494			15,231			43,716			69,966
	b) Pharmaceutical Services and Active Ingredients		67			(794	)		256			(883	)		353
	c) Others		147			73			47			494			1,419
	Total		(2,927	)		1,773			15,534			43,327			71,738

	Less: (i) Finance costs		543			414			311			1,483			1,099
	(ii) Other un-allocable (income)/expenditure, net		(415	)		317			(395	)		(669	)		(1,720	)
	Total profit/(loss) before tax		(3,055	)		1,042			15,618			42,513			72,359

Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost.

Segmental capital employed

As certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.

DR. REDDY’S LABORATORIES LIMITED

Balance sheet

All amounts in Indian Rupees millions

	As at		As at
	31.03.2026		31.03.2025
Particulars	(Audited)		(Audited)
ASSETS
Non-current assets
Property, plant and equipment		77,527		58,654
Capital work-in-progress		13,691		21,564
Goodwill		853		853
Other intangible assets		28,921		22,817
Intangible assets under development		-		404
Financial assets
Investments		123,613		103,105
Loans		5		14
Other financial assets		2,686		8,562
Tax assets, net		2,650		1,244
Other non-current assets		843		662
Total non-current assets		250,789		217,879

Current assets
Inventories		49,556		45,758
Financial assets
Investments		32,335		28,830
Trade receivables		41,186		59,590
Derivative instruments		39		539
Cash and cash equivalents		3,375		3,197
Other bank balances		16,201		6,571
Loans		1,002		-
Other financial assets		19,351		910
Other current assets		22,187		19,635
Total current assets		185,232		165,030

TOTAL ASSETS		436,021		382,909

EQUITY AND LIABILITIES
Equity
Equity share capital		835		834
Other equity		312,821		287,732
Total Equity		313,656		288,566

Liabilities
Non-current liabilities
Financial liabilities
Lease liabilities		2,501		765
Provisions		120		54
Deferred tax liabilities, net		5,899		5,154
Other non-current liabilities		2,420		1,852
Total non-current liabilities		10,940		7,825

Current liabilities
Financial liabilities
Borrowings		54,190		33,855
Lease liabilities		679		309
Trade payables
Total outstanding dues of micro enterprises and small enterprises		316		210
Total outstanding dues of creditors other than micro enterprises and small enterprises		18,726		19,721
Derivative instruments		6,785		1,273
Other financial liabilities		20,268		19,955
Other current liabilities		6,320		7,006
Tax Liabilities, net		1,072		794
Provisions		3,069		3,395
Total current liabilities		111,425		86,518

TOTAL EQUITY AND LIABILITIES		436,021		382,909

DR. REDDY’S LABORATORIES LIMITED

Statement of cash flows

All amounts in Indian Rupees millions

	Year ended			Year ended
	31.03.2026			31.03.2025
Particulars	(Audited)			(Audited)
Cash flows from/(used in) operating activities :
Profit before tax		42,513			72,359
Adjustments for:
Fair value changes and profit on sale of financial instruments measured at FVTPL*, net		(2,052	)		(3,128	)
Depreciation and amortisation expense		12,074			10,394
Impairment of non-current assets, net		1,405			1,036
Allowance for credit losses (on trade receivables and other advances)		175			103
Loss /(Profit) on sale/disposal of assets, net		(2,074	)		428
Unrealized exchange (gain)/loss, net		(3,117	)		(116	)
Interest income		(7,771	)		(4,825	)
Finance costs		1,483			1,099
Equity settled share-based payment expense		299			382
Inventories write-down		4,488			2,771
Changes in operating assets and liabilities:
Trade receivables		18,278			(13,451	)
Inventories		(8,287	)		(8,340	)
Trade payables		(889	)		(517	)
Other assets and other liabilities, net		(447	)		(81	)
Cash generated from operations		56,078			58,114
Income taxes paid, net		(9,473	)		(15,864	)
Net cash generated from operating activities		46,605			42,250

Cash flows from/(used in) investing activities :
Purchase of property, plant and equipment		(20,492	)		(23,393	)
Proceeds from sale of property, plant and equipment		258			323
Purchase of other intangible assets		(8,888	)		(1,374	)
Proceeds from sale of other intangible assets		980			104
Purchase of investments (including bank deposits)		(41,354	)		(22,484	)
Proceeds from sale of investments (including bank deposits)		14,968			52,788
Investments in subsidiary/associates		(5,791	)		(67,541	)
Interest/dividend income received		3,463			3,998
Loans and advances given to subsidiaries		(1,050	)		(57	)
Loans and advances repaid by subsidiaries		59			660
Net cash used in investing activities		(57,847	)		(56,976	)

Cash flows from/(used in) financing activities :
Proceeds from issuance of equity shares (including treasury shares)		397			193
Purchases of treasury shares		-			(1,389	)
Proceeds from short-term loans and borrowings, net		20,281			25,840
Payment of principal portion of lease liabilities		(382	)		(281	)
Dividend paid		(6,659	)		(6,662	)
Interest paid		(2,469	)		(1,794	)
Net cash from financing activities		11,168			15,907

Net increase/(decrease) in cash and cash equivalents		(74	)		1,181
Effect of exchange rate changes on cash and cash equivalents		252			2
Cash and cash equivalents at the beginning of the year		3,197			2,014
Cash and cash equivalents at the end of the year		3,375			3,197

*FVTPL (fair value through profit or loss)

DR. REDDY’S LABORATORIES LIMITED

Notes:

1	The above statement of audited standalone financial results of Dr. Reddy’s Laboratories Limited (“the Company”), which have been prepared in accordance with the Indian Accounting Standards (’‘Ind AS’’) prescribed under Section 133 of the Companies Act, 2013 (“the Act’’) read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (“SEBI’’) were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 12 May 2026. The Statutory Auditors have issued an unqualified report thereon.

2	Revenue from sale of goods for the quarter ended 31 March 2026 includes the consequential impact of reduction in selling price of Lenalidomide product in the United States of USD 50 million. This transaction pertains to the company’s Global Generics segment.

3	“License fees and service income” for the year ended 31 March 2025 includes an amount of Rs. 8,113 million (excluding GST) received as a consideration towards transfer of its nutraceutical and vitamins, minerals, herbals, and supplements portfolio to Dr. Reddy’s and Nestlé Health Science Limited (the “Nutraceuticals subsidiary”) as part of the definitive agreement. This transaction pertains to Company’s Global Generics segment.

4	During the quarter ended 31 March 2026, the Company has decided to discontinue certain of its R&D programs associated with Chimeric Antigen Receptor T-cell (CAR-T) therapy portfolio in light of current development status and recent clinical trial outcomes. Consequent to this decision, the Company has recognized a net loss of Rs. 1,350 million in the Company’s Global Generics segment, comprising of : a. Impairment of non-current assets of Rs. 1,135 million (i.e., towards Property, plant and equipment, Intangibles and Right of use assets), b. Research and development cost reimbursment to subsidiary of Rs.198 million and c. Other development program related wind down cost of Rs. 17 million.

5	“Impairment of non-current assets, net” for the year ended 31 March 2025 primarily includes: a. an impairment loss of Rs. 862 million (31 March 2024: Rs. 288 million) towards investment in equity shares and preference shares in the subsidiary, Svaas Wellness Limited, consequent to management’s decision to scale down the business operations of certain digital initiatives. This impairment loss pertains to the Company’s Others segment. b. an impairment loss of Rs. 174 million, consequent to adverse market conditions with respect to certain product related intangibles forming part of the Company’s Global Generics segment.

6	“Other income” for the quarter ended 31 March 2026 includes gain on sale of non-current assets, net of Rs. 1,890 million towards divestment of certain product related intangibles i.e., trademarks.

7	In respect of the field tax audit report from the Federal Tax Service authority relating to one of its foreign subsidiaries for the period from January 2020 to December 2022, based on its best estimate, the Company had recorded a provision of Rs. 695 million under “Other Expenses” during the three months ended 30 September 2025. On 23 March 2026, pursuant to the final order from the Federal Tax Service authorities the originally proposed VAT liability was substantially reduced. Based on the final order, an additional provision of Rs. 1,141 million, including applicable interest and penalties, was recognized for the periods covered under audit as well as subsequent period from calendar year 2023 through 31 March 2026. This additional provision was recorded under “Other Expenses” during the quarter ended 31 March 2026. The Company believes that the likelihood of any further liability on account of this field tax audit is not probable. This transaction pertains to the Company’s Global Generics segment.

8	The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code 2020 (collectively referred to as the “New Labour Codes”). The New Labour Codes are effective from 21 November 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The New Labour Codes have implications on employee benefits including gratuity, leave encashment, and other related obligations. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs.1,101 million towards employee benefits during the year ended 31 March 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to and the impact of these will be accounted in accordance with applicable accounting standards.

DR. REDDY’S LABORATORIES LIMITED

9	The Company received an anonymous complaint in September 2020, alleging that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of U.S. anti-corruption laws, specifically the U.S. Foreign Corrupt Practices Act. The Company disclosed the matter to the U.S. Department of Justice (“DOJ”), Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India. The Company engaged a U.S. law firm to conduct the investigation at the instruction of a committee of the Company’s Board of Directors. On 6 July 2021 the Company received a subpoena from the SEC for the production of related documents, which were provided to the SEC. The Company engaged with the SEC and DOJ, including through submissions and presentations regarding the initial complaint and additional complaints relating to other markets, and in relation to its Global Compliance Framework, which included enhancement initiatives undertaken by the Company, and the Company complied with its listing obligations as it relates to updating the regulatory agencies. On 23 February 2026 the Company received a letter from the SEC stating that, based on the information available to it, the SEC has concluded its investigation and does not intend to recommend any enforcement action against the Company at this time. On 5 March 2026, the Company received a letter from the DOJ stating that, based on the information available to it, the DOJ has closed its inquiry.

10	The Company considered the uncertainties relating to geo-political conflicts (including Russia and Ukraine) in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgments, estimates and assumptions, the Company expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.

11	The Board of Directors, at their meeting held on 12 May 2026, have recommended a final dividend of Rs.8 per share subject to the approval of shareholders.

12	The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the relevant financial year. Also the figures upto the end of third quarter were only reviewed and not subjected to audit.

	By order of the Board
	For Dr. Reddy’s Laboratories Limited


Place: Hyderabad	G V Prasad
Date: 12 May 2026	Co-Chairman & Managing Director
	DIN: 00057433

Exhibit Number		Description of Exhibits

99.1		Outcome of the Board Meeting held on May 12, 2026

99.2		Press Release, “Dr. Reddy’s Q4 FY2026 Financial Results”, May 12, 2026.

99.3		IFRS Audited Consolidated Financial Results for the quarter and year ended March 31, 2026.

99.4		Ind AS Audited Consolidated Financial Results for the quarter and year ended March 31, 2026.

99.5		Ind AS Audited Standalone Financial Results for the quarter and year ended March 31, 2026.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)

Date: May 12, 2026	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary & Compliance Officer

[6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Positive

Negative

Insights

Filing Exhibits & Attachments

Press Releases

[6-K] DR REDDYS LABORATORIES LTD Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Positive

Negative

Insights

Equity analyst negative

Filing Exhibits & Attachments

Press Releases